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Lack of awareness of pulmonary arterial hypertension 
(PAH) on the part of both patients and caregivers, 
and failure of public and private funders to provide 
resources for the management of the disease, have 
meant that patients have little or no access to any of 
the treatments approved by international guidelines.
Recognising the plight of patients with PAH, interested individuals 
were invited to participate in the First Joint South African Heart 
Association (SA Heart)/South African Thoracic Society (SATS) 
Working Group Meeting, held at O R Tambo Airport, Johannesburg, 
South Africa (SA), on 23 May 2014. The meeting received official 
recognition from both SA Heart and SATS. The members of the 
Working Group Writing Committee of SA Heart/SATS wrote this 
article and are listed above as authors.
1.  Format of the joint Working  
Group Meeting
The meeting was co-chaired by Prof. M R Essop (cardiologist) 
and Dr P Williams (pulmonologist). Two international experts 
representing Europe and North America participated in the lectures 
and discussions. Prof. N Galie from Bologna University, Italy, is 
chairman of the European Guideline Committee on PAH and 
guest editor of the Journal of the American College of Cardiology 
supplement on the Proceedings of the 5th World Society of Pulmonary 
Hypertension. Prof. D Badesch from the Division of Pulmonary 
Sciences, Critical Care Medicine and Cardiology, University of 
Colorado, USA, is an author of the American Guidelines on PAH. 
Both have published extensively and have been senior investigators in 
pivotal trials on PAH. In addition, representatives of patient interest 
groups and medical funders were invited to give their perspective.
The Joint SA Heart/SATS Working Group Committee concluded 
that local medical expertise should remain current and not lag 
behind other developing nations. While PAH remains an uncommon 
disease, it affects mainly younger people and has a prognosis worse 
than those of most malignancies, and therefore merits treatment. 
Although treatment is expensive, it is probably in proportion to that 
of other diseases with a poor prognosis. The prognosis of PAH is 
steadily improving as a result of advances in medical therapy, and SA 
patients should have access to these. In this regard, there is an urgent 
need for introduction and registration of at least one drug from each 
of the four major therapeutic classes.
Consequently, the Committee unanimously resolved to: (i) 
increase awareness of PAH, promoting education and research 
and establishing databases and registries; (ii) provisionally adopt 
the European Guidelines for PAH[1] as a working document for SA 
while making amendments pertinent to the practice of medicine in 
this country; (iii) engage with funders to provide essential therapies 
to patients with PAH; (iv) inform the Medicines Control Council of 
the need to expedite approval of essential therapies and encourage 
suppliers of such therapies to provide these at an optimal cost given 
SA’s financial constraints; and (v) serve as arbitrator when there are 
conflicting views on how a patient with PAH should be managed 
best.
2.  Pulmonary arterial hypertension
PAH is a disorder of the pulmonary arterioles characterised by 
endothelial proliferation, fibrointimal hyperplasia and in situ 
thrombosis with progressive obstructive vasculopathy, pulmonary 
hypertension and eventually right ventricular failure and death. 
Despite significant progress, there are large gaps in the understanding 
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of the pathogenic mechanisms and 
determinants of progression of PAH. The 
grim prognosis highlights the need for 
earlier recognition, intensive management, 
and further clinical and laboratory research.
The recently published classification of 
PAH, repres enting consensus of the 5th 
World Symposium held in Nice, France, in 
2013, recognises five groups of pulmonary 
hypertension.[2] The term PAH is reserved 
specifically for group 1 (Table 1).
2.1 Aetiology of PAH
About 20% of patients with idiopathic PAH 
and 80% of those with heritable PAH have a 
mutation of the bone morphogenetic protein 
receptor (BMPR2) gene, a member of the 
super-family of TGF proteins. Although 
the exact mechanism by which BMPR2 
mutations result in the PAH phenotype is 
unclear, inhibition of apoptosis with clonal 
proliferation of endothelial cells is thought 
to play a role.
Autoimmune diseases most frequently 
associated with PAH include scleroderma 
and lupus erythematosus. Not infrequently, 
idiopathic PAH may be associated with 
low positive titres of autoantibodies, 
making it difficult to distinguish it from 
PAH secondary to autoimmune disease. 
Consultation with a rheumatologist in these 
cases is essential.
PAH occurs in 0.5% of patients with HIV 
and is associated with a poor prognosis.
2.2 Epidemiology of PAH
Ascertaining the true incidence of PAH 
is difficult, as the onset is insidious and 
the diagnosis challenging. Furthermore, 
symptoms and signs of right ventricular 
dysfunction and reduction in cardiac output 
occur when the disease is already advanced. 
The estimated prevalence of PAH in the 
developed world ranges from 5 to 15 per 
million adults.[3] There is no reason to 
believe that the prevalence in SA is any 
different. With the huge burden of HIV, a 
cause of PAH indistinguishable from the 
idiopathic type, it is likely that there is a large 
undiagnosed population with this disease.[4]
2.3 Diagnosis of PAH
A diagnostic algorithm is shown in Fig. 1.
Symptoms of PAH include dyspnoea, 
fatigue, chest pain, syncope and ankle 
swelling. Clinical signs lack sensitivity, but 
in advanced disease include tachycardia, 
left parasternal heave, loud pulmonary 
component of the second heart sound, 
murmurs of tricuspid or pulmonary 
regurgitation, and evidence of systemic 
venous congestion. Electrocardiography 
characteristically shows right axis deviation 
and right ventricular hypertrophy. The 
proximal pulmonary arteries are dilated 
on the chest radiograph, with attenuation 
of distal vessels together with evidence of 
right atrial and ventricular enlargement. 
Echocardiography remains the most useful 
investigation, allowing measurement of 
pulmonary artery systolic pressure, exclusion 
of left heart disease and congenital shunts, 
and assessment of right ventricular function. 
Cardiac catheterisation is the gold standard 
for diagnosis of PAH and in addition allows 
assessment of disease severity, exclusion 
of category 2 pulmonary hypertension 
caused by left heart disease, and testing of 
pulmonary vasoreactivity.
2.4 Treatment of PAH
PAH patients with vasoreactivity are treated 
with high-dose calcium channel blockers 
such as nifedipine. Four classes of drugs are 
available for non-reactive patients, including 
the prostacyclin agonists, endothelin receptor 
blockers, PDE5 inhibitors, and most recently 
agents that increase availability of cyclic 
guanosine monophosphate. Combinations of 
these various classes of drugs seem to be the 
way forward, but the optimal permutation is 
still the subject of ongoing research. Other 
treatments include diuretics, digitalis and 
Table 1. The Nice classification of pulmonary hypertension[5]
1.  Pulmonary arterial hypertension
1.1  Idiopathic PAH
1.2  Heritable PAH
1.3  Drug- and toxin-induced PAH
1.4  PAH associated with:
1.4.1  Autoimmune disease
1.4.2  HIV
1.4.3  Portal hypertension
1.4.4  Congenital heart disease
1.4.5  Schistomiasis
1’   Pulmonary veno-occlusive disease, pulmonary capillary haemangiomatosis
1’’   Persistent pulmonary hypertension of the newborn
2.  Pulmonary hypertension due to left heart disease
2.1  Left ventricular systolic dysfunction
2.2  Left ventricular diastolic dysfunction
2.3  Valvular disease
2.4   Congenital/acquired left heart inflow/outflow obstruction and familial 
cardiomyopathies
3.  Pulmonary hypertension due to lung diseases or hypoxia
3.1  Chronic obstructive pulmonary disease
3.2  Interstitial lung disease
3.3  Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4  Sleep-disordered breathing
3.5  Alveolar hypoventilation disorders
3.6  Chronic exposure to high altitude
3.7  Developmental lung diseases
4.  Chronic thromboembolic pulmonary hypertension
5.  Pulmonary hypertension with unclear multifactorial mechanisms
5.1   Haematological disorders: chronic haemolytic anaemia, myeloproliferative disease, 
splenectomy
5.2  Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis
5.3  Metabolic disorders: glycogen storage disease, Gaucher’s disease, thyroid disorders
5.4   Others: tumour obstruction, fibrosing mediastinitis, chronic renal failure, segmental 
pulmonary hypertension
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ambulatory oxygen with sequential lung 
transplantation for class 4 patients resistant 
to all pharmacological agents.
2.5 Prognosis of PAH
Modern targeted pharmacological therapy 
for PAH has reduced mortality by about 
40%. Nevertheless, survival is 58% at 5 years, 
indicating a need for more effective disease-
modifying therapies.
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Fig. 1. Diagnostic algorithm for patients with suspected pulmonary hypertension. (ECG = 
electrocardiography; CXR = chest radiograph; PH = pulmonary hypertension; ABG = arterial blood 
gas; ANF = antinuclear factor; LFTs = liver function tests; PFT = pulmonary function tests; TOE = 
transoesophageal echocardiography; V/Q = ventilation-perfusion scan; CTPA = CT pulmonary 
angiogram; CT = computed tomography.)
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